Post-Marketing Safety Study of Ramucirumab Plus FOLFIRI: Analysis of Age and Initial Dose of Irinotecan in Patients with Metastatic Colorectal Cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Post-Marketing Safety Study of Ramucirumab Plus FOLFIRI: Analysis of Age and Initial Dose of Irinotecan in Patients with Metastatic Colorectal Cancer ; day:27 ; month:4 ; year:2023 ; pages:1-9
Drugs - real world outcomes ; (27.4.2023), 1-9
- Creator
-
Masuishi, Toshiki
Nagaoka, Soshi
Jin, Long
Yoshizawa, Kenichi
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40801-023-00366-2
- URN
-
urn:nbn:de:101:1-2023090321015462995724
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:46 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Masuishi, Toshiki
- Nagaoka, Soshi
- Jin, Long
- Yoshizawa, Kenichi
- SpringerLink (Online service)
Other Objects (12)
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients
Correction to: Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
Aflibercept with FOLFIRI in Japanese patients with metastatic colorectal cancer: results of a post-marketing surveillance
Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity
Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study
Jugular Foramen Syndrome as Initial Presentation of Metastatic Lung Cancer
Inguinal Lymphadenopathy: A Rare Initial Site of Metastatic Lung Carcinoma
Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis
Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase
EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer
Type and dose of radiotherapy used for initial treatment of non-metastatic prostate cancer
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients
Correction to: Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
Aflibercept with FOLFIRI in Japanese patients with metastatic colorectal cancer: results of a post-marketing surveillance
Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity
Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study
Jugular Foramen Syndrome as Initial Presentation of Metastatic Lung Cancer
Inguinal Lymphadenopathy: A Rare Initial Site of Metastatic Lung Carcinoma
Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis
Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase
EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer
Type and dose of radiotherapy used for initial treatment of non-metastatic prostate cancer
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients
Correction to: Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
Aflibercept with FOLFIRI in Japanese patients with metastatic colorectal cancer: results of a post-marketing surveillance
Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity
Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study
Jugular Foramen Syndrome as Initial Presentation of Metastatic Lung Cancer
Inguinal Lymphadenopathy: A Rare Initial Site of Metastatic Lung Carcinoma
Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis
Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase
EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer